Patient-reported Outcomes in the Treatment of Schizophrenia

Solvay

Status and phase: Completed; Phase 3

Conditions: Schizophrenia

Treatments: Drug: bifeprunox

Study type: Interventional

Funder types: Industry

Identifiers

NCT00230828

S154.3.005

Details and patient eligibility

About

Patient-reported health economic outcomes for patients enrolled in S1543003 and S1543004 protocols

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participate in S1543003 and S1543004 in the U.S. sites

Exclusion criteria

• Participate in S1543003 and S1543004 other than U.S. sites

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: Double Blind